France Residual DNA Testing Market (2025-2030)
The France Residual DNA Testing Market was valued at $6.1 Million in 2025 and projected to reach to $7.7 Million by 2030, representing a compound annual growth rate of 4.9%. France's residual DNA testing market demonstrates steady growth potential driven by stringent pharmaceutical manufacturing standards and increasing regulatory scrutiny of product quality.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
France Residual DNA Testing Market Trends and Insights
- This moderate growth trajectory reflects France's established healthcare infrastructure and regulatory framework governing molecular diagnostics.
- France's market development is driven by increasing adoption of residual DNA testing in pharmaceutical quality control, forensic applications, and clinical diagnostics, supported by stringent European Union compliance standards. The French residual DNA testing market benefits from strong pharmaceutical manufacturing presence and advanced laboratory capabilities across the country.
- France's commitment to precision medicine and quality assurance in drug manufacturing continues to support steady demand for residual DNA testing solutions.
- Between 2025 and 2030, France is expected to see incremental market expansion as healthcare providers and manufacturers invest in advanced testing methodologies to meet evolving regulatory requirements and improve product safety standards..
Key Market Statistics
- CAGR (2025-2030) 4.9% CAGR
- Market Size, 2025 ~USD 6.1 Million
- Forecast, 2030 ~USD 7.7 Million
- Country France
France Residual DNA Testing Market Overview
Market Valuation :
France's residual DNA testing market is valued at $6.1 million in 2025, with projected growth to $7.7 million by 2030, representing a steady CAGR of 4.9%.
Regulatory Environment :
France maintains a robust regulatory framework for molecular diagnostics under EU guidelines, ensuring quality standards and compliance that support market stability and healthcare provider confidence.
Healthcare Infrastructure :
France's established healthcare system and advanced laboratory capabilities provide a solid foundation for residual DNA testing adoption across clinical and pharmaceutical research settings.
Growth Drivers :
Increasing adoption of residual DNA testing in pharmaceutical quality control, bioanalytical validation, and clinical diagnostics is propelling moderate but consistent market expansion in France.
France Residual DNA Testing Market Dynamics
- The French healthcare sector's emphasis on precision medicine and molecular diagnostics creates sustained demand for residual DNA testing solutions across pharmaceutical companies, contract research organizations, and clinical laboratories. The moderate 4.9% CAGR reflects France's mature market characteristics and established quality control practices.
- Growth will be supported by expanding bioanalytical services, increased investment in pharmaceutical R&D, and heightened awareness of contamination risks in manufacturing processes.
- France's alignment with EU regulatory requirements positions it as a key market for residual DNA testing technologies..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Thermo Fisher Scientific Inc.
- Merck KGaA
- SANOFI
- Pfizer Inc.
- NOVARTIS
Key Takeaways
- France's residual DNA testing market is valued at $6.1 million in 2025 with projected growth to $7.7 million by 2030.
- France experiences a 4.9% CAGR, reflecting steady but moderate market expansion driven by pharmaceutical quality control demands.
- France's strong regulatory environment and EU compliance requirements support consistent adoption of residual DNA testing technologies.
- France's established pharmaceutical manufacturing sector and advanced laboratory infrastructure position it as a stable market for molecular diagnostics.
Residual DNA Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | CELL & GENE THERAPY (Application) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 16.4% from 2025 to 2030 |
| Largest Segment | POLYMERASE CHAIN REACTION (Technology) |
| Market Size Base Year (Billions) | ~USD 0.17 (2025) |
| Revenue Forecast (Billions) | ~USD 0.37 (2030) |
| Segments Covered | Offering, Type, Test Type, Technology, Application, End User |
France Residual DNA Testing Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Consumables
- Instruments & Software
By Test Type
- Bulk Lot Release Testing
- Final Product Release Testing
- Raw Material Testing
By Technology
- Dna Probe Hybridization
- Other Technologies
- Polymerase Chain Reaction
- Threshold Assays
By Application
- Cell & Gene Therapy
- Monoclonal Antibodies
- Other Applications
- Vaccines
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Pharmaceutical & Biopharmaceutical Companies
- Pharmaceutical & Biotechnology Companies
FRANCE: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 1.4 | 1.5 | 1.6 | 1.6 | 1.7 | 1.8 | 1.9 | 2.1 | 5.9 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 3.7 | 3.9 | 4.1 | 4.4 | 4.7 | 5 | 5.4 | 5.8 | 6.9 |
| TOTAL | 5.1 | 5.4 | 5.7 | 6 | 6.4 | 6.8 | 7.3 | 7.9 | 6.6 |
FRANCE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER,2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 0.55 | 0.56 | 0.57 | 0.58 | 0.59 | 0.61 | 0.63 | 0.66 | 3 |
| CROS & CDMOS | 1.13 | 1.16 | 1.19 | 1.23 | 1.27 | 1.33 | 1.4 | 1.49 | 4.6 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 4.06 | 4.18 | 4.32 | 4.49 | 4.69 | 4.94 | 5.23 | 5.57 | 5.2 |
| TOTAL | 5.74 | 5.89 | 6.07 | 6.29 | 6.56 | 6.88 | 7.26 | 7.72 | 4.9 |
Target Audience
- Pharmaceutical Manufacturers : Need France-specific market data to optimize residual DNA testing protocols, ensure regulatory compliance, and benchmark quality control practices against industry standards in French operations.
- Contract Research Organizations (CROs) : Require detailed market insights to expand bioanalytical testing services in France, identify client demand patterns, and develop competitive service offerings aligned with French pharmaceutical sector needs.
- Diagnostic Laboratory Operators : Seek market intelligence to assess growth opportunities, understand service demand trends, and make informed investment decisions in residual DNA testing capabilities within France.
- Medical Device & Diagnostics Companies : Need France market analysis to evaluate expansion opportunities, understand regulatory pathways, and develop product strategies tailored to French healthcare and pharmaceutical sectors.
- Healthcare Consultants & Investors : Require comprehensive France market data to support due diligence, identify investment opportunities, and provide strategic recommendations to clients operating in the French diagnostics sector.
Key Companies in the France Residual DNA Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Consumables (assay kits, reagents, plastics),Instruments (PCR, qPCR, automation),Software & informatics, |
| CHARLES RIVER LABORATORIES | United States | Public Company | Consumables (assay reagents, kits within services),Instruments & Software (PCR and data platforms used in labs),Services – Raw Material Testing, |
| MERCK KGAA | United States | Public Company | Consumables (reagents, kits, assay components),Instruments,Software & Services (including CDMO/CRO testing support), |
| MARAVAI LIFESCIENCES | United States | Public Company | Consumables,Instrument & Software,Services, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Consumables,Instrument & Software,PCR-based Testing Services, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Consumables,Instruments,Software & Informatics, |
| QIAGEN | Netherlands | Public Company | Consumables (sample prep, PCR, assays),Instruments (PCR, sample prep, QC),Software & Bioinformatics, |
| FUJIFILM CORPORATION | Japan | Public Company | Consumables (reagents, kits, media-linked components),Instruments & Software (PCR platforms, analytics, workflow tools),PCR-based Testing Services (CDMO-integrated), |
| SGS SOCIÉTÉ GéNéRALE DE SURVEILLANCE SA. | Switzerland | Public Company | Consumables-linked testing services,Instrument & software-enabled testing services,PCR-based residual DNA testing (all test types), |
| REVVITY | United States | Public Company | Consumables (reagents, assay kits, cartridges),Instruments,Software & Services, |
| INTERTEK GROUP PLC | United Kingdom | Public Company | Consumables,Instruments & Software,PCR-based Testing Services, |
| SARTORIUS AG | United States | Public Company | Consumables (filters, reagents, lab plastics linked to residual DNA workflows),Instruments (bioreactors, filtration systems, analytical platforms used in DNA-controlled processes),Software & data analytics (lab data, PAT, and QC integration), |
| LONZA | Switzerland | Public Company | Consumables,Instruments & Software,PCR-based Testing Services, |
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a leading global provider of life sciences solutions, founded in 1956 and headquartered in the United States. With 125,000 employees, the company operates as a public corporation serving research, diagnostics, and bioproduction markets worldwide.
CHARLES RIVER LABORATORIES
Charles River Laboratories is a contract research organization founded in 1947, providing preclinical and clinical laboratory services to the pharmaceutical and biotechnology industries. The U.S.-based public company employs 19,000 people and supports drug development and safety testing globally.
MERCK KGAA
Merck KGaA is a diversified science and technology company founded in 1668, operating as a public company with 59,077 employees across the United States and globally. The company serves the pharmaceutical, life sciences, and performance materials sectors.
MARAVAI LIFESCIENCES
Maravai LifeSciences is a U.S.-based public company founded in 2014, specializing in critical reagents and services for the life sciences industry. With 416 employees, the company supports vaccine development, gene therapy, and molecular diagnostics.
EUROFINS SCIENTIFIC
Eurofins Scientific is a Luxembourg-based public company founded in 1987, operating a global network of laboratories with 65,694 employees. The company provides testing and analytical services across pharmaceutical, food, environmental, and consumer product sectors.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a U.S. public company founded in 1952, manufacturing and distributing life science research and clinical diagnostics products. With 7,450 employees, the company serves research institutions, hospitals, and laboratories worldwide.
QIAGEN
QIAGEN is a Netherlands-based public company founded in 1984, specializing in sample and assay technologies for molecular diagnostics and life sciences research. The company employs 5,500 people and serves clinical, pharmaceutical, and academic markets globally.
FUJIFILM CORPORATION
Fujifilm Corporation is a Japanese multinational public company founded in 1934, with 73,526 employees operating across imaging, information, and life sciences divisions. The company provides diagnostic imaging, pharmaceutical, and biotechnology solutions worldwide.
SGS SOCIÉTÉ GéNéRALE DE SURVEILLANCE SA.
SGS Société Générale de Surveillance SA. is a Switzerland-based public company founded in 1878, employing 83,000 people in inspection, verification, testing, and certification services. The company serves industries including pharmaceuticals, food, and consumer goods globally.
REVVITY
Revvity is a U.S.-based public company founded in 1937, providing analytical instruments, software, and services for research and diagnostics. With 11,000 employees, the company supports life sciences, diagnostics, and environmental testing applications.
INTERTEK GROUP PLC
Intertek Group PLC is a United Kingdom-based public company founded in 1885, employing 45,425 people in testing, inspection, and certification services. The company serves industries including pharmaceuticals, chemicals, and consumer products across the globe.
SARTORIUS AG
Sartorius AG is a U.S.-based public company founded in 1870, manufacturing laboratory and bioprocess equipment with 14,242 employees. The company provides filtration, weighing, and bioanalytical solutions for pharmaceutical and life sciences applications.
LONZA
Lonza is a Switzerland-based public company founded in 1897, employing 20,000 people in pharmaceutical and biotechnology manufacturing and services. The company specializes in custom development and manufacturing, cell therapy, and specialty ingredients.
Reasons to Buy this Report
- Regulatory Compliance Insights : Understand France's specific regulatory requirements and EU compliance standards for residual DNA testing, enabling pharmaceutical companies to navigate market entry and operational requirements effectively.
- Market Sizing & Forecasting : Access precise market valuation data for France ($6.1M in 2025) with detailed 5-year forecasts to support strategic planning, investment decisions, and resource allocation in the French market.
- Competitive Landscape Analysis : Identify key players, service providers, and competitive dynamics specific to France's residual DNA testing sector to inform partnership strategies and market positioning.
- Growth Opportunity Assessment : Evaluate the 4.9% CAGR trajectory and underlying growth drivers in France to identify high-potential segments within pharmaceutical manufacturing, CROs, and clinical diagnostics.
- Strategic Market Entry Planning : Leverage France-specific market intelligence to develop targeted go-to-market strategies, identify customer segments, and optimize resource deployment in this established European market.
Frequently asked questions
What is the current market size of residual DNA testing in France?
France's residual DNA testing market is valued at $6.1 million in 2025, based on verified market data.
What is the projected market size for residual DNA testing in France by 2030?
France's residual DNA testing market is forecast to reach $7.7 million by 2030, representing growth from the 2025 baseline.
What is the growth rate of the residual DNA testing market in France?
France's residual DNA testing market is growing at a compound annual growth rate (CAGR) of 4.9% from 2025 to 2030.
What factors drive residual DNA testing demand in France?
France's market is driven by pharmaceutical quality control requirements, EU regulatory compliance, forensic applications, and clinical diagnostic adoption across healthcare facilities.
How does France's market compare to global residual DNA testing trends?
France's 4.9% CAGR is more conservative than the global 16.4% CAGR, reflecting France's mature healthcare market and established regulatory framework.
RESEARCH METHODOLOGY
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global residual DNA testing market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used primarily to identify & collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, World Health Organization (WHO), United States Food and Drug Administration (US FDA), National Center for Biotechnology Information (NCBI), Health Canada, European Medicines Agency (EMA), and Centers for Disease Control and Prevention (CDC). These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative & quantitative information and assess the prospects of the market. Various primary sources from both the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the residual DNA testing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
The total market was split into several segments and subsegments after arriving at the overall market size from the estimation process. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Residual DNA testing involves the detection and quantification of DNA impurities from host cells present in biopharmaceutical products. This testing is a critical component in the quality assurance of biologics, as it assesses the levels of residual DNA that may remain in the final product, bulk intermediates, or raw materials post-purification. The market for residual DNA testing encompasses a diverse array of analytical tools and services tailored to meet stringent regulatory requirements. Compliance with guidelines established by the FDA, WHO, and GxP standards necessitates a thorough evaluation of host cell DNA to mitigate risks and ensure safety and efficacy in biologics. This regulatory landscape makes residual DNA testing a vital focus area in the development and manufacturing of biologic products, emphasizing the need for precision and reliability in these assessments.
Stakeholders
- Pharmaceutical & biotechnology companies
- Academic researchers and government research organizations
- Private research institutes
- Custom residual DNA testing service providers
- Contract development & manufacturing organizations (CDMOs)
- Life Science Companies
- Contract research organizations (CROs)
- Market research & consulting firms
- Venture capitalists
Report Objectives
- To define, describe, and forecast the global residual DNA testing market by offering, technology, test type, application, end user (product), end user (service), and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall residual DNA testing market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- Track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the residual DNA testing market.
- To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the residual DNA testing market.
Get the Full Residual DNA Testing Market Report
Full forecast, segment splits, and company analysis for all Residual DNA Testing Market.
- Rest Of Europe Residual DNA Testing Market
- Rest Of Asia Pacific Residual DNA Testing Market
- Rest Of Latin America Residual DNA Testing Market
- Rest Of GCC Countries Residual DNA Testing Market
- Saudi Arabia Residual DNA Testing Market
- GCC Countries Residual DNA Testing Market
- Rest Of Middle East Residual DNA Testing Market
- Canada Residual DNA Testing Market
- US Residual DNA Testing Market
- Germany Residual DNA Testing Market
- UK Residual DNA Testing Market
- Italy Residual DNA Testing Market
- Spain Residual DNA Testing Market
- China Residual DNA Testing Market
- Japan Residual DNA Testing Market
- India Residual DNA Testing Market
- South Korea Residual DNA Testing Market
- Australia Residual DNA Testing Market
- Brazil Residual DNA Testing Market
- Mexico Residual DNA Testing Market
- UAE Residual DNA Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
